Skip to main content
EJNMMI Radiopharmacy and Chemistry
Fig. 5 | EJNMMI Radiopharmacy and Chemistry

Fig. 5

From: [225Ac]Ac- and [111In]In-DOTA-trastuzumab theranostic pair: cellular dosimetry and cytotoxicity in vitro and tumour and normal tissue uptake in vivo in NRG mice with HER2-positive human breast cancer xenografts

Fig. 5

a Tumour and normal tissue uptake at 48 h p.i. of [111In]In-DOTA-trastuzumab (7–8 MBq) coinjected with [225Ac]Ac-DOTA-trastuzumab (4 kBq; total mass dose = 40 µg) in NRG mice with s.c. HER2-positive 164/8-1B/H2N.luc + human BC tumours. B: blood, Br: brain, H: heart, Lu: lungs, K: kidneys, Pn: pancreas, Sp: spleen, L: liver, S: stomach, I: intestine, Sk: skin, M: muscle, Bo: bone. Tissue activity was quantified by γ-counting of 111In. Values shown are the mean ± SD (n = 4–5). Significant differences (*P < 0.05) are indicated by asterisks. b Representative SPECT/CT images of tumour-bearing NRG mice at 48 h p.i. of [111In]In-DOTA-trastuzumab coinjected with [225Ac]Ac-DOTA-trastuzumab (left image) or [111In]In-DOTA-IgG1 coinjected with [225Ac]Ac-DOTA-IgG1 (right image). T: tumour, Sp: spleen. Scale for SPECT/CT images shows the percent injected dose/g (%ID/g). Also shown in grayscale is the scale for the CT image

Back to article page